Syvac® EH Marker: the first and unique DIVA vaccine against EHD
The AEMPS authorises Syvac® EH Marker, the first and only DIVA vaccine against Epizootic Haemorrhagic Epizootic Disease (EHD) virus from Syva PRESS RELEASE: León – Technology Parc – Spain, 16 October 2024
Syva is pleased to announce that the Spanish Agency for Medicines and Health Products has authorized the emergency use of its DIVA vaccine against EHD in accordance with Article 110 (2) of Regulation (EU) 2019/6 in cattle and deer.
SYVAC® EH Marker is the first and unique subunit vaccine against this disease available on the European market. This innovative process using ‘subunit’ technology allows differentiation between infected and vaccinated animals, a benefit for the control of this emerging disease.
Epizootic haemorrhagic disease, a silent but very real threat in Europe!
The first cases of serotype 8 epizootic haemorrhagic disease were reported in November 2022, in Italy. Almost at the same time, outbreaks were detected in southern Spain, in Extremadura and Andalusia, spreading soon after to a large number of farms all over Spain. Later, in September 2023, France reported the first outbreaks of the disease.
Although it does not affect humans, EHD is one of the vector-borne diseases, caused by an Orbivirus similar to Bluetongue, whose serotype 3 (BTV3) was identified in 2023 in Europe and that has recently been detected in Spain, severely affecting ruminants, especially sheep and cattle.
Vaccination is the most effective method to prevent and control both Bluetongue and Epizootic Haemorrhagic Disease, and in the case of EHD, having a DIVA vaccine available for the first time in Europe is a step forward and a key innovation for the control of the disease.
EHD serotype 8 vaccine: Syva opts for innovation and DIVA technology.
Syva decided to provide an innovative vaccine with a decisive added value that is enabling a DIVA strategy to be implemented in the future, offering to veterinarians and livestock farmers a useful and effective tool in the battle against this epizootic.
But what is a DIVA vaccine?
DIVA stands for ‘Differentiation between Infected and Vaccinated Animals’. Syvac® EH Marker is based on so-called subunit technology. A subunit vaccine only contains parts (or ‘subunits’) of a virus or bacteria, rather than the entire micro-organism. These subunits are virus-specific proteins that the immune system can recognise to trigger the desired immune response in the vaccinated animals.
Marker vaccines induce an immune response different from the one induced by a natural infection. In the context of EHD, as in other notifiable diseases, Syvac® EH Marker means a turning point in the fight against the disease.
Download here the Press release
ABOUT Syvac® EH Marker
Syvac® EH Marker injectable emulsion is the first and only subunit vaccine that provides differentiated protection against EHD in cattle and deer. It is the only EHDV vaccine on the EU market that currently allows differentiation between infected and non-infected animals. Furthermore, it is conveniently administered in 2 ml intramuscular doses.
For more information, see the product page on our website .
You may also be interested in
30 January, 2025
Syvac® EH Marker, the first and only DIVA vaccine against EHD, is now authorized in Belgium
Syva is pleased to announce that the FAMHP/FAGG has granted emergency use authorization for its marker (DIVA) vaccine against EHD in accordance with Article 110(2) of Regulation (EU) 2019/6 for use in cattle and deer.
24 January, 2025
Call for the 28th edition of the Syva Award International for the best doctoral thesis in Animal Health
We are pleased to remind you that the call for applications for the 28th Syva Award International is open until 18 February 2025. We also remind you that for two years now, the Syva Award International is no longer limited to Spanish candidates, but invites all doctoral students of any nationality who have submitted their thesis in animal health...
22 January, 2025
Syva receives a positive opinion for Syvazul BTV 3 vaccine from the CVMP of the European Medicines Agency (EMA).
On 15 January 2025, the Committee for Medicinal Products for Veterinary Use (CVMP) issued a positive opinion recommending the granting of a marketing authorization for Syvazul BTV 3 vaccine. This step forward marks an important milestone in the fight against Bluetongue, and Syva is proud to be at the forefront of this innovation.
Media tool kit
We provide users, particularly journalists and the press, with a series of graphic documents, photographs and videos. We offer the free use of these documents under certain conditions
Journalist and Press Contact
Are you a journalist, part of the press or the media? Do you want to get information on our activities, validate your sources in a professional manner, obtain validated photographic material or request an interview?
Next Events
